- Home
- STEP vs FOLD Comparison
STEP vs FOLD Comparison
Compare STEP & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | STEP | FOLD |
|---|---|---|
| Founded | 2007 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.5B |
| IPO Year | 2020 | 2006 |
Fundamental Metrics
Financial Performance| Metric | STEP | FOLD |
|---|---|---|
| Price | $55.60 | $14.49 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 9 |
| Target Price | ★ $71.00 | $27.25 |
| AVG Volume (30 Days) | 824.3K | ★ 2.5M |
| Earning Date | 05-21-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.98% | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,174,830,000.00 | N/A |
| Revenue This Year | N/A | $20.50 |
| Revenue Next Year | $26.41 | $18.59 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 65.09 | N/A |
| 52 Week Low | $40.58 | $5.66 |
| 52 Week High | $77.80 | $14.50 |
Technical Indicators
Market Signals| Indicator | STEP | FOLD |
|---|---|---|
| Relative Strength Index (RSI) | 60.48 | 74.18 |
| Support Level | $49.48 | $14.21 |
| Resistance Level | $63.91 | N/A |
| Average True Range (ATR) | 2.53 | 0.02 |
| MACD | 0.11 | -0.00 |
| Stochastic Oscillator | 73.30 | 100.00 |
Price Performance
Historical ComparisonAbout STEP StepStone Group Inc.
StepStone Group Inc operates as a fully integrated private markets solution provider. The company provides customized investment solutions and advisory and data services. It provides investment solutions in the areas of private equity, real estate, private debt, and infrastructure and real assets. The company consists of a single operating segment and a single reportable segment for accounting and financial reporting purposes.
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.